Publish date: Mar 14, 2023
true
BD Onclarity™ HPV test accepted for use in NHS Cervical Screening Programme for primary HPV screening
WINNERSH, U.K., 14 March 2023 – BD (Becton, Dickinson and Company), a leading medical technology company, announced the NHS England (NHSE) approval of their BD Onclarity™ HPV Assay for HPV primary screening on the BD COR™ system, extending our options for HPV screening in the UK. The BD Onclarity™ HPV test is CE-marked for HPV screening for clinician-taken cervical specimens and at-home or in clinic self-collected vaginal specimen.1 The vaginal specimen is as good as the clinician-taken cervical specimens,2 giving women the reassurance and confidence to carry out their Human papillomavirus (HPV) testing in the comfort of their own home.
Every year approximately 3,200 women are diagnosed with cervical cancer in the UK,3 making it the 14th most common cancer among women in the country,3 yet 1 in 3 women across the UK are not up to date with their cervical screening tests.4 Several barriers to screening persist across the country, including limited access to health services and low awareness of cervical cancer screening.5
Cervical cancer is highly preventable through cervical screening.6 BD offers the BD Onclarity™ HPV Assay for use on the BD Viper™ LT System and the BD COR™ System. The assay allows for at-home collection of vaginal swab samples making it more convenient, easy, accessible, and potentially less uncomfortable for women compared to clinician-taken cervical samples.7 BD’s test can identify 14 high-risk HPV types with a single analysis. The newly approved BD Onclarity™ HPV test is to be performed on the BD COR™ system. It is also validated for a wide range of sample types:
- Liquid-based cytology specimens
- Cervical brush specimens
- Self-collected vaginal specimens
Self-sampling has been shown to increase participation in women who do not currently attend regular screenings8 and is favoured over clinician-led screening.9 Studies have also shown home screening kits can increase participation from ethnic and underserved communities.10
Bruce Caldwell, Country Business Leader for Integrated Diagnostic Solutions, BD UKI commented:
“At BD we are committed to delivering excellent solutions to customers and supporting their diagnostic journeys. We are supporting the efforts to end cervical cancer in the UK and want to support women and their families with our solution for self-collection in human papillomavirus (HPV) screening. This is a significant milestone for the future of cervical screening and BD are proud to support this advancement.”
Persistent infection with one of 14 high-risk genotypes of HPV is a necessary, but not sufficient cause of cervical cancer.11 The BD Onclarity™ HPV Assay offers extended genotyping in a single sample-to-result run, providing detailed, accurate results to help identify the risk of cervical disease more precisely, with individual results for six HPV genotypes and three strategic grouped results for the other eight high-risk HPV genotypes.1
For media enquiries or to get in touch, click here.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
true
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
true
true
